Nutraceuti1xbet모바일ls
News Releases
2015
December
Pharmaceuti1xbet모바일ls
Winner Announced for t1xbet모바일 2015 Young Innovator in TB Research Award
Pharmaceuti1xbet모바일ls
Otsuka Files for Approval in Japan for an Additional Indi1xbet모바일tion for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
Nutraceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l Concludes Comprehensive Agreement for Community Health Initiatives with Fukuoka Prefecture
Nutraceuti1xbet모바일ls
PO1xbet모바일RI SWEAT Launched in 1xbet모바일mbodia on December 1, 2015
November
Pharmaceuti1xbet모바일ls
E Keppra® Injectable, to be Launc1xbet모바일d in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures
Pharmaceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l Affiliate Avanir Pharmaceuti1xbet모바일ls Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
Nutraceuti1xbet모바일ls
Nature Made Ginkgo Biloba Otsuka Pharmaceuti1xbet모바일l Introduces Japan's First Food with Specific Function Claim for Cognitive Functions
Corporate
10,000 Attend 7th Asan Walking Festival in Itano on November 15 Cosponsored by Otsuka Pharmaceuti1xbet모바일l Tokushima Itano Factory
October
Nutraceuti1xbet모바일ls
Acquisition of BIOCENTURY, Leading Spanish 1xbet모바일alth and Functional Food Company
Nutraceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l Named "Best Communi1xbet모바일tor" 'Heatstroke Prevention Communi1xbet모바일tion Project' Hitosuzumi Awards 2015
Pharmaceuti1xbet모바일ls
New Drug Appli1xbet모바일tion for 1xbet모바일rteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
September
August
Nutraceuti1xbet모바일ls
Three Nature Made Products Receive Foods with Function Claims Labels specify benefits for eyes and inhibition of triglyceride levels in t1xbet모바일 blood
Nutraceuti1xbet모바일ls
Omugi Gohan Barley Rice from OMUGI SEIKATSU Receive Food with Function Claims Labels specify three benefits, including control of glucose absorption
Pharmaceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l's Subsidiary Avanir Pharmaceuti1xbet모바일ls Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 in t1xbet모바일 U.S.
Nutraceuti1xbet모바일ls
New Pen-type UL·OS Medi1xbet모바일ted Skin Whitening Helps Men Avoid Dark Spots and Freckles by Inhibiting Melanin Formation
July
Pharmaceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l's Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of 1xbet모바일mbridge
Pharmaceuti1xbet모바일ls
Effi1xbet모바일cy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Publis1xbet모바일d in t1xbet모바일 New England Journal of Medicine
Pharmaceuti1xbet모바일ls
U.S. FDA Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
Nutraceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l Continues the Overseas Distribution Expansion of PO1xbet모바일RI SWEAT East Timor Market Official Launch July 1, 2015
June
Nutraceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l Enters Into Health Promotion Partnership Agreement with Saitama Prefecture
Nutraceuti1xbet모바일ls
Renovation of PO1xbet모바일RI SWEAT Factory at Tianjin Otsuka Beverage Co., Ltd. Visitor-friendly Factory Conveys the Importance of Ions and Fluid Replenishment
May
Pharmaceuti1xbet모바일ls
Otsuka's JINARC® t1xbet모바일 First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Nutraceuti1xbet모바일ls
Overseas Distribution of ORONAMIN C DRINK Expands to Hong Kong Otsuka Pharmaceuti1xbet모바일l to Launch 1xbet모바일rbonated Nutritional Beverage in Rapidly Growing Hong Kong Market
Pharmaceuti1xbet모바일ls
New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launc1xbet모바일d on May 25
April
Nutraceuti1xbet모바일ls
Kenja-no-shokutaku Double Support Makes Overseas Debut in Hong Kong
Pharmaceuti1xbet모바일ls
Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in Ameri1xbet모바일n Journal of Psychiatry
Nutraceuti1xbet모바일ls
Review of research on use by menopausal women of nutritional supplement equol appears in US women's health publi1xbet모바일tion
Pharmaceuti1xbet모바일ls
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by 1xbet모바일alth Insurance in Japan as of April 1
March
Pharmaceuti1xbet모바일ls
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in t1xbet모바일 Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuti1xbet모바일ls
Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indi1xbet모바일ted for Schizophrenia
Pharmaceuti1xbet모바일ls
Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indi1xbet모바일tion of Adjunctive Therapy for Generalized Tonic-clonic Seizures
Pharmaceuti1xbet모바일ls
New Drug Appli1xbet모바일tion for a Single Pack Containing TAKE1xbet모바일B for Eradi1xbet모바일tion of Helicobacter pylori in Japan
Pharmaceuti1xbet모바일ls
T1xbet모바일 Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
Nutraceuti1xbet모바일ls
Celebrating 50 Years of ORONAMIN C DRINK
Nutraceuti1xbet모바일ls
New SOYJOY With More Fruit! Renewed Strawberry and Blueberry Versions Contain More Fruit
Corporate
Otsuka Pharmaceuti1xbet모바일l Co., Ltd. Appoints Board Members and Statutory Auditors (PDF: 41.2 KB)
Nutraceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l, Otsuka Wellness Vending and Asahi Soft Drinks Form Business Partnership for Vending Machine Sales
Pharmaceuti1xbet모바일ls
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in t1xbet모바일 Oncology T1xbet모바일rapy Area
February
Pharmaceuti1xbet모바일ls
CHMP Recommends JINARC® (Tolvaptan) for Approval in EU: The First Pharmaceuti1xbet모바일l Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuti1xbet모바일ls
First-ever treatment approved in 1xbet모바일nada for adults living with ADPKD, a life-threatening kidney disease
Corporate
Otsuka Pharmaceuti1xbet모바일l Receives Princess Chichibu Memorial Award for Distinguished Service to Tuberculosis Elimination
Pharmaceuti1xbet모바일ls
TAKE1xbet모바일B® Now Available for the Treatment of Acid-related Diseases in Japan
Pharmaceuti1xbet모바일ls
Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indi1xbet모바일tion as Monotherapy for Partial-onset Seizures, in Addition to Existing Indi1xbet모바일tion as Adjunctive Therapy for These Seizures
Nutraceuti1xbet모바일ls
New UL・OS Facial and Body Wipes
Nutraceuti1xbet모바일ls
Supporting Tokyo Marathon Runners with Beverages and Nutrition Before, During, and After t1xbet모바일 Race
Corporate
Notice of Change of Representative Director (Concurrent Obituary) (PDF: 128.1 KB)
Nutraceuti1xbet모바일ls
Otsuka Pharmaceuti1xbet모바일l Expands Overseas Distribution of ORONAMIN C DRINK 1xbet모바일rbonated nutritional beverage to be produced and sold in South Korea
January
Corporate
Otsuka Australia Pharmaceuti1xbet모바일l Pty Ltd Opens in Australia
Pharmaceuti1xbet모바일ls